Eli Lilly’s Mounjaro (tirzepatide) is now FDA-approved to reduce cardiovascular risk in adults with type 2 diabetes (T2D). Given as a once-weekly subcutaneous injection, tirzepatide is the first dual GIP and GLP-1 receptor agonist shown to lower the risk for heart attack, stroke, or cardiovascular death in those with T2D at high risk for these …
Read More
Mounjaro FDA-Approved to Reduce Cardiovascular Risk in T2D
